Newswise — HERCULES, Calif– July 25, 2017 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced the addition of four new analytes to the company’s Liquichek Tumor Marker Control. The updated control has received FDA 510(k) clearance and CE marking and is available for the immunoassay-based tumor marker testing market.


The Immunoassay-based tumor marker testing market is considered one of the major growth areas in immunoassay testing and is estimated to reach $1.4 billion by 2021 according to a 2016 report by research firm Kalorama Information. 


This enhanced Liquichek Tumor Marker Control features HE4 and HER-2/neu. Along with these analytes, Liquichek Tumor Marker Control offers low levels of Prostate-Specific Antigen (PSA), high levels of cancer antigens, and the protein Ferritin. (The other newly added analytes to Liquichek Tumor Marker Control: ProGRP and SCC are only available outside the U.S.)



About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit


This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “offers,” or similar expressions or the negative of those terms or expressions, although not all

Page 2 of 2



forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


Press Contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia, Corporate Communications 

510-724-7000 [email protected]